DE10348319A1 - Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques - Google Patents

Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques Download PDF

Info

Publication number
DE10348319A1
DE10348319A1 DE10348319A DE10348319A DE10348319A1 DE 10348319 A1 DE10348319 A1 DE 10348319A1 DE 10348319 A DE10348319 A DE 10348319A DE 10348319 A DE10348319 A DE 10348319A DE 10348319 A1 DE10348319 A1 DE 10348319A1
Authority
DE
Germany
Prior art keywords
seq
xaa
use according
amino acid
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10348319A
Other languages
German (de)
English (en)
Inventor
Dieter Heldmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to DE10348319A priority Critical patent/DE10348319A1/de
Priority to PCT/EP2004/011654 priority patent/WO2005037312A2/de
Priority to EP04790493A priority patent/EP1684804A2/de
Priority to JP2006534712A priority patent/JP4755103B2/ja
Priority to US10/966,097 priority patent/US20050112690A1/en
Publication of DE10348319A1 publication Critical patent/DE10348319A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE10348319A 2003-10-17 2003-10-17 Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques Withdrawn DE10348319A1 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE10348319A DE10348319A1 (de) 2003-10-17 2003-10-17 Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques
PCT/EP2004/011654 WO2005037312A2 (de) 2003-10-17 2004-10-15 Bindemoleküle für die extra-domäne b von fibronectin zur detektion von atherosklerotischen plaques
EP04790493A EP1684804A2 (de) 2003-10-17 2004-10-15 Bindemoleküle für die extra-domäne b von fibronectin zur detektion von atherosklerotischen plaques
JP2006534712A JP4755103B2 (ja) 2003-10-17 2004-10-15 動脈硬化性プラークの検出のために使用されるフィブロネクチンのドメインｂ外ドメインのための結合分子
US10/966,097 US20050112690A1 (en) 2003-10-17 2004-10-18 Binding molecules for the extra-domain B of fibronectin for detection of arteriosclerotic plaque

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10348319A DE10348319A1 (de) 2003-10-17 2003-10-17 Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques

Publications (1)

Publication Number Publication Date
DE10348319A1 true DE10348319A1 (de) 2005-05-19

Family

ID=34442038

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10348319A Withdrawn DE10348319A1 (de) 2003-10-17 2003-10-17 Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques

Country Status (5)

Country Link
US (1) US20050112690A1 (https=)
EP (1) EP1684804A2 (https=)
JP (1) JP4755103B2 (https=)
DE (1) DE10348319A1 (https=)
WO (1) WO2005037312A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524018A (ja) * 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
WO2008046510A1 (en) * 2006-10-16 2008-04-24 Bayer Healthcare Ag Fn1 as a biomarker, therapeutic and diagnostic target
EP1917980A1 (en) * 2006-10-31 2008-05-07 Bayer Schering Pharma Aktiengesellschaft Use of a fusion protein between a cytokine and an antibody targeting the ED-B fibronectin domain for the treatment of atherosclerosis
WO2011110490A1 (en) 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft Process for the production of radioactively labelled scfv antibody fragments, kits and compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
JP2003524018A (ja) * 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
AU2003210149B2 (en) * 2002-01-03 2008-10-09 Bayer Schering Pharma Aktiengesellschaft Conjugates comprising an antibody specific for the ED-B domain of fibronectin and their use for the detection and treatment of tumours

Also Published As

Publication number Publication date
EP1684804A2 (de) 2006-08-02
JP2007508352A (ja) 2007-04-05
JP4755103B2 (ja) 2011-08-24
US20050112690A1 (en) 2005-05-26
WO2005037312A2 (de) 2005-04-28
WO2005037312A3 (de) 2005-06-23

Similar Documents

Publication Publication Date Title
DE69423908T2 (de) Antikörper gegen das carcinoembryonic antigen
Oliveira et al. Peptide-based fibrin-targeting probes for thrombus imaging
US6580016B2 (en) Animal model for detection of vulnerable plaques
AU2012298487B2 (en) Anti-VCAM-1 nanobodies
EP2152369B1 (de) Verwendung von fluorhaltigen verbindungen zu diagnosezwecken mit hilfe bildgebender verfahren
US20140065069A1 (en) Materials and Methods Relating to Cardiovascular Imaging
DE10348319A1 (de) Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques
US20060257389A1 (en) Diagnosis of blood clots using fibrin-binding proteins bound with contrast agents
DE69530375T2 (de) Radioaktiv-markierte annexine
AU2012324981A1 (en) Method and unit for the processing of sunflower-extraction meal
Bickel et al. Pharmacokinetic differences between 111in-and 125i-labeled cationized monoclonal antibody against β-amyloid in mouse and dog
DD297064A5 (de) Reagens zum nachweis der fibrinolytischen aktivitaet
DE2621311A1 (de) Verfahren zum markieren von proteinen mit technetium 99 hoch m
Ji et al. Detection of pulmonary embolism with 99mTc-labeled F (ab) 2 fragment of anti-P-selectin monoclonal antibody in dogs
CN115998910B (zh) 一种靶向ha的核素小分子蛋白探针及其应用
King et al. Platelet imaging of thromboembolism: natural history of postoperative deep venous thrombosis and pulmonary embolism illustrated using the 111In-labelled platelet-specific monoclonal antibody, P256
US9637542B2 (en) CX3CR1-targeting imaging agents and their use in the diagnosis and treatment of disease
Ouadi et al. Imaging thrombosis with 99mTc-labeled RAM. 1-antibody in vivo
Ji et al. Detection of Thromboembolism with 99mTc-labeled F (ab) 2 Fragment of Anti-glycoprotein IIIa Chimeric Monoclonal Antibody in Beagle Canines
WO2003050499A2 (de) Verwendung eines markierten liganden mit spezifität für das humane cd4-molekül
DE102010026052A1 (de) 11C-markiertes Peptid zur Detektion eines krankhaften Gewebes, das einen IGF-Rezeptor exprimiert
Baudhuin Imaging of vulnerable plaques in atherosclerosis with radiolabeled nanobodies targeting Macrophage Mannose Receptor
US20100061934A1 (en) Methods for diagnosis or treatment of amyloidosis by targeting hyper-sulfated proteoglycans present in amyloid
DE102010026059A1 (de) 11C-markiertes Peptid zur Detektion eines krankhaften Gewebes, das einen Chemokinrezeptor exprimiert
DE10232189A1 (de) Verwendung eines markierten Liganden mit Spezifität für das humane CD4-Molekül zur Herstellung eines Diagnostikums zur Analyse von Wanderungs- und/oder Verteilungsmustern von Zellpopulationen

Legal Events

Date Code Title Description
8181 Inventor (new situation)

Inventor name: DINKELBORG, LUTGER, DR., 13465 BERLIN, DE

Inventor name: HELDMANN, DIETER, 13509 BERLIN, DE

8127 New person/name/address of the applicant

Owner name: BAYER SCHERING PHARMA AG, 13353 BERLIN, DE

8127 New person/name/address of the applicant

Owner name: BAYER SCHERING PHARMA AKIENGESELLSCHAFT, 13353, DE

8141 Disposal/no request for examination